My research focus on clustered signaling pathways of molecular partners in defined subcellular compartments (signalosomes) that enables cells to exert highly specialized tasks. Actually, our goal for the future is to unravel the organization of the recently discovered signaling components within functional units by biochemical, molecular, cell biological methods, genetic and omic’s. Research is embedded in the field of integrative pharmacology and translational medicine. We have directed our attention to chronic inflammatory disorders, as evidence exist for a role of our signaling components (Epac, PLD, AKAP, cofilin) in smooth muscle cells, neuronal cells, immune cells as well as cardiomyocytes. Many devastating diseases, e.g. cancer, type-II diabetes mellitus, Alzheimers’s dementia, cardiovascular and airway diseases (heart failure, cardiac arrhythmia, developmental defects, asthma and COPD), and infection diseases are associated with defective or derailed signaling processes, and research into the control of these processes clearly is of great public and social importance as well. My research group integrates in vivo, ex vivo translational pharmacology, molecular (cell) biology. Novel techniques like microfluidics, precision cut tissue slices and others.

Dr Anh Nguyen is an ARC DECRA Research Fellow and Head of GPCR EcoPharmacology Lab at Monash Institute of Pharmaceutical Sciences. Her research focuses on decoding drug-receptor interactions at G protein-coupled receptors (GPCRs) to drive the discovery of next-generation therapeutics, particularly allosteric and biased ligands, for cardiovascular and neuronal diseases. She leads an innovation-driven program that integrates molecular pharmacology, computational modelling, high-throughput screening, and artificial intelligence to develop a cutting-edge GPCR-targeted drug discovery platform. Dr Nguyen also pioneers research into how environmental pollutants, especially micro- and nanoplastics, disrupt GPCR signalling, contributing to cardiovascular and neurodegenerative diseases. As head of a multidisciplinary team, she drives transformative approaches in pharmacology and invites workshop participants to explore the future of AI in drug development.

Dr Jake Martin is an ecologist and ecotoxicologist whose research explores how human-driven environmental change affects wildlife. He uses a combination of laboratory experiments, fieldwork, and meta-analysis to investigate the impacts of emerging chemical pollutants in aquatic ecosystems, with a particular focus on how pharmaceuticals influence animal behaviour. After completing his PhD and first postdoctoral role at Monash University, Jake moved to Sweden as a Formas Mobility Fellow, holding a joint position at the Swedish University of Agricultural Sciences (SLU) and Stockholm University. He is now an Alfred Deakin Research Fellow at Deakin University, where his research focuses on animal–microbe symbioses and the spatial and temporal dynamics of contaminant exposure.

I am a medical doctor, a trainee in clinical pharmacology, and I am currently working as a pharmacotherapy teacher at Amsterdam UMC. In addition, I am pursuing a PhD in environmentally sustainable prescribing at Amsterdam UMC, for which I am conducting research at the University of Sydney this year (2026). I also coordinate the Erasmus+ project 'Planetary Health Education in Prescribing' (PlanED Prescribing), which aims to integrate environmental sustainability into prescribing practices and medical education across Europe and beyond.